-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio to host virtual commercial day on tinlarebant opportunity in Stargardt disease type 1

PUBT·08/24/2026 20:00:20
Listen to the news
Belite Bio to host virtual commercial day on tinlarebant opportunity in Stargardt disease type 1
  • Belite Bio will host a virtual Commercial Day on Sept. 2, 2026, from 8:00 a.m. to 9:30 a.m. ET.
  • Event will outline the commercial opportunity for tinlarebant in Stargardt disease type 1, contingent on U.S. FDA clearance.
  • FDA accepted the tinlarebant NDA for STGD1 with Priority Review; PDUFA action date set for Feb. 12, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608241600PRIMZONEFULLFEED9815152) on August 24, 2026, and is solely responsible for the information contained therein.